Internal R&D is still critical, but externally sourced products are increasingly representing more in revenue.
By Kevin Shannon, Analyst
30 September 2016
I am an analyst at Datamonitor Healthcare, currently located in San Diego, California, where I am a member of the cardio...
Read full bio
The majority of overweight and obese patients seeking treatment in the markets analyzed do not receive pharmacological weight loss therapy, despite the fact that most of these patients meet the criteria established by treatment guidelines. Even within the most severe categorization of obesity (body mass index [BMI] >40.0), less than 50% of patients were reported to receive pharmacological treatment in most countries. This is an extraordinarily low rate of treatment for a disease where approved pharmacological options are available. Current guidelines recommend considering weight loss drugs as an adjuvant to lifestyle changes in patients with a BMI of ≥30.0, or ≥27.0 with an additional co-morbidity (Jensen et al., 2014).
The relatively unattractive clinical profiles of current weight loss therapies may be limiting the patient share captured by pharmacological treatments. Current drugs are associated with moderate weight loss efficacy and several concerns regarding tolerability and safety. The most effective pharmacotherapy on the market, Qsymia (phentermine/topiramate; Vivus), is only able to produce a mean weight loss of approximately 6.6–9.4kg in conjunction with behavioral and lifestyle modifications. Greater efficacy than this will be required to drive uptake and overcome concerns surrounding tolerability and safety in this market, despite studies suggesting weight loss of this magnitude may have tangible clinical benefits.
Datamonitor Healthcare’s Obesity: Treatment provides a detailed look at patient segmentation, current prescribing patterns and key treatment challenges in obesity.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>